ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).

Nirajan GhosalPoulami TapadarDivisha BiswasRanjana Pal

Published in: Molecular biology reports (2024)

Our study shows ELF3 to be an important factor that can influence TRAIL-mediated apoptosis in breast cancer. Also, ELF3 and DCR2 expression status should be taken into consideration while designing strategies for successful TRAIL-based therapy.

Keyphrases

poor prognosis
binding protein
signaling pathway
stem cells
long non coding rna
bone marrow